Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - moxifloxacinum hýdróklóríð - augndropar, lausn - 5 mg/ml

Evrópusambandið - íslenska - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - kyrningahvítblæði, mergbólga - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - kyrningahvítblæði, mergbreytilegt, langvinnt, bcr-abl jákvætt - Æxlishemjandi lyf - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - donepezil hydrochloride - filmuhúðuð tafla - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - donepezil hydrochloride - filmuhúðuð tafla - 5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - fluoxetine hydrochloride - lausnartafla - 20 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf - fluoxetine hydrochloride - hart hylki - 20 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

h. lundbeck a/s* - sertindolum inn - filmuhúðuð tafla - 4 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - sýklalyf fyrir almenn nota, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

orion corporation - toremifene - brjóstakrabbamein - innkirtla meðferð - hormónahvörf fyrstu hormónabundinna brjóstakrabbameins með meinvörpum hjá sjúklingum eftir tíðahvörf. fareston er ekki mælt með því fyrir sjúklinga með estrógen viðtaka neikvæð æxli.